FACACLASSIC

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.

Details on agency responses to committee recommendations can be found under the Performance Measures section for each committee in the fields “Agency Feedback” and “Agency Feedback Comment.”

DOD - 9484 - Uniform Formulary Beneficiary Advisory Panel - Statutory (Congress Created)

GENERAL INFORMATION

Committee Name	Uniform Formulary Beneficiary Advisory Panel	Agency Name	Department of Defense
Fiscal Year	2025	Committee Number	9484
Original Establishment Date	10/5/1999	Committee Status	Chartered
Actual Termination Date		Committee URL	https://www.health.mil/Military-Health-Topics/A...
Actual Merged Date		Presidential Appointments*	No
New Committee This FY	No	Max Number of Members*	15
Terminated This FY	No	Designated Fed Officer Position Title*	DFO
Merged This FY		Designated Federal Officer Prefix	CAPT
Current Charter Date	8/1/2024	Designated Federal Officer First Name*	Tiffany
Date Of Renewal Charter	8/1/2026	Designated Federal Officer Middle Name	F.
Projected Termination Date		Designated Federal Officer Last Name*	Cline
Exempt From Renewal*	No	Designated Federal Officer Suffix
Specific Termination Authority		Designated Federal Officer Phone*	(703) 681-2890
Establishment Authority*	Statutory (Congress Created)	Designated Federal Officer Fax*
Specific Establishment Authority*	10 U.S.C. § 1074g(c)	Designated Federal Officer Email*	dha.ncr.j-6.mbx.baprequests@health.mil
Effective Date Of Authority*	10/5/1999
Exempt From EO 13875 Discretionary Cmte	Not Applicable
Committee Type*	Continuing
Presidential*	No
Committee Function*	Scientific Technical Program Advisory Board

RECOMMENDATION/JUSTIFICATIONS

Agency Recommendation*	Continue
Legislation to Terminate Required	Not Applicable
Legislation Status	Not Applicable
How does cmte accomplish its purpose?*	The Panel will meet an estimate of four times a year to review and comment on the development of the Uniform Formulary by the DoD Pharmacy and Therapeutics Committee. The Director, Defense Health Agency is required to consider the comments of the panel before making his final decision.
How is membership balanced?*	The Panel's membership includes family members of active duty and retired military personnel, members of retiree organizations, TRICARE healthcare contractors, and medical professionals from outside of DoD.
How frequent & relevant are cmte mtgs?*	Per the Charter, the estimated number of Panel meeting is 4 per year. DoD implemented its Congressionally-mandated 3-tier Uniform Formulary (UF) in 2005 which required development of a transparent formulary management process that accesses medications for formulary status based on an evidence-based clinical and cost-effectiveness evaluation; open/equitable price competition; and to establish the Beneficiary Advisory Panel (BAP) which provides an opportunity for beneficiaries to comment on the DoD Pharmacy and Therapeutics Committee's formulary recommendations before approval by the DHA Director. The BAP concept is unique to DoD. It provides transparency and credibility from a beneficiary perspective to the UF process.Unlike private sector health plans, the DoD uses more disclosure of the evidence presented and allows beneficiaries to provide input before implementation of formulary changes. A major focus of the BAP is the process of formulary decision implementation, especially the process of communication with the 9.7 million TRICARE beneficiaries. For example, the BAP can recommend a longer implementation period for medications moved to Non-Formulary (Tier 3) to balance between allowing necessary time for beneficiary notification versus cost considerations. Moreover, feedback from the BAP was instrumental in the DoD's decision to start sending targeted letters to affected beneficiaries during the up to 180-day implementation period. Implementation periods have been lengthened on several occasions supporting communication with beneficiaries.
Why advice can't be obtained elsewhere?*	Mandated by law to review and comment on recommdenations by the DoD Pharmacy and Therapeutics Committee regarding DoD's Uniform Formulary.
Why close or partially close meetings?	Meetings are not closed to the public unless the Department of Defense determines that items on the planned agenda meet the closed meeting provisions of 5 U.S.C. § 552b(c). Pursuant to DoD policy closed meetings can only be authorized by the DoD Sponsor (i.e., the Under Secretary of Defense for Personnel and Readiness), and only after consultation with the Office of the Department of Defense General Counsel.
Recommendation Remarks	Due to the Secretary of Defense's pause of all advisory committee operations effective March 7, 2025 and the conclusion of all committee member appointments effective April 25, 2025, the Panel did not meet in FY 2025.

PERFORMANCE MEASURES

Outcome Improvement To Health Or Safety*	Yes	Action Reorganize Priorities*	No
Outcome Trust In Government	Yes	Action Reallocate Resources	No
Outcome Major Policy Changes	No	Action Issued New Regulations	No
Outcome Advance In Scientific Research	No	Action Proposed Legislation	No
Outcome Effective Grant Making	No	Action Approved Grants Or Other Payments	No
Outcome Improved Service Delivery	No	Action Other	No
Outcome Increased Customer Satisfaction	Yes	Action Comment	NA
Outcome Implement Laws/Reg Requirements	Yes	Grants Review*	No
Outcome Other	No	Number Of Grants Reviewed	0
Outcome Comment	NA	Number Of Grants Recommended	0
Cost Savings*	None	Dollar Value Of Grants Recommended	$0.00
Cost Savings Comment	The recommendations made by the Panel do not attribute to a cost savings to the Department of Defense.	Grants Review Comment	NA
Number Of Recommendations*	1,368	Access Contact Designated Fed. Officer*	Yes
Number Of Recommendations Comment	Due to the lack of membership in the UF BAP, the panel made zero (0) recommendations during FY 2025, to address the FY 2025 DoD Pharmacy and Therapeutics Committee meetings. The Panel makes comments to the DoD Pharmacy and Therapeutics Committee recommendations for changes to the Uniform Formulary, implementation timelines, and prior authorization criteria. To date the Panel has made 1368 recommendations. This includes the 0 recommendations made in FY 2025.	Access Agency Website	Yes
% of Recs Fully Implemented*	0.00%	Access Committee Website	Yes
% of Recs Fully Implemented Comment	The Director, Defense Health Agency, is required to consider the Panel's comments prior to her final decisions.	Access GSA FACA Website	Yes
% of Recs Partially Implemented*	0.00%	Access Publications	No
% of Recs Partially Implemented Comment	The committee may recommend a shorter or longer implementation period. They may also reject a recommendation. The Director, Defense Health Agency makes the final decision.	Access Other	No
Agency Feedback*	Yes	Access Comment	N/A
Agency Feedback Comment*	Minutes from the DoD Pharmacy & Therapeutics Committee and Uniform Formulary Beneficiary Advisory Panel are posted and available to Panel members.	Narrative Description*	The Uniform Formulary Beneficiary Advisory Panel provides a forum for input into the development and sustainment of the pharmacy benefit for all Department of Defense (DoD) beneficiaries.

COSTS

1. Payments to Non-Federal Members*	$0.00	1. Est Paymnts to Non-Fed Membrs Nxt FY*	$0.00
2. Payments to Federal Members*	$0.00	2. Est. Payments to Fed Members Next FY*	$0.00
3. Payments to Federal Staff*	$65,000.00	3. Estimated Payments to Federal Staff*	$67,000.00
4. Payments to Consultants*	$0.00	4. Est. Payments to Consultants Next FY*	$0.00
5. Travel Reimb. For Non-Federal Membrs*	$0.00	5. Est Travel Reimb Non-Fed Membr nxtFY*	$0.00
6. Travel Reimb. For Federal Members*	$0.00	6. Est Travel Reimb For Fed Members*	$0.00
7. Travel Reimb. For Federal Staff*	$0.00	7. Est. Travel Reimb to Fed Staf Nxt FY*	$0.00
8. Travel Reimb. For Consultants*	$0.00	8. Est Travel Reimb to Consltnts Nxt FY*	$0.00
10. Other Costs	$0.00	10. Est. Other Costs Next FY*	$0.00
11. Total Costs	$65,000.00	11. Est. Total Next FY*	$67,000.00
Date Cost Last Modified	9/16/2025 10:59 AM	Est. Fed Staff Support Next FY*
Federal Staff Support (FTE)*	0.35	Est Cost Remarks	0.35
Cost Remarks	The Uniform Formulary Beneficiary Advisory Panel (UFBAP) members’ service have been concluded per SECDEF direction after the DoD advisory committee 45-day review. The cost section of this report will show $0 cost, due to not having UF BAP meetings this year.

Interest Areas

Category Area Food and Drugs Biotechnology Food and Drugs Medical Devices Government Federal Government Health Health Care Safety Legislation Rulemaking Medicine Health and Health Research Veterans Veterans and Veterans' Medical Care

Custom Links

Committee Level Reports